Lenvanix 10 mg contains Lenvatinib, an orally active, multi-targeted tyrosine kinase inhibitor (TKI) used in the treatment of various advanced and progressive cancers. Lenvatinib works by inhibiting multiple receptor tyrosine kinases involved in tumor growth, angiogenesis, and cancer progression. By targeting these pathways, Lenvanix helps slow tumor development and spread, making it an important option in modern targeted cancer therapy.

Lenvatinib exerts its anticancer effect by blocking vascular endothelial growth factor (VEGF) receptors, fibroblast growth factor (FGF) receptors, platelet-derived growth factor (PDGF) receptors, and other kinases associated with tumor blood vessel formation and malignant cell proliferation. Inhibition of these pathways reduces tumor vascularization, depriving cancer cells of nutrients and oxygen required for growth.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Lenvanix 10 mg is indicated for the treatment of:

• Differentiated thyroid cancer (DTC) that is locally recurrent or metastatic and refractory to radioactive iodine therapy.

• Advanced renal cell carcinoma (RCC), often in combination with other anticancer agents, as prescribed by an oncologist.

• Unresectable hepatocellular carcinoma (HCC) in patients who have not received prior systemic therapy.

• Other approved oncology indications as per clinical guidelines and physician discretion.

Therapeutic Class

• Antineoplastic Agent

• Multikinase Inhibitor / Tyrosine Kinase Inhibitor

Pharmacology

Lenvatinib selectively inhibits multiple kinases that play a critical role in tumor angiogenesis and cancer cell survival. By targeting VEGFR 1–3 and FGFR 1–4, along with additional signaling receptors, Lenvanix effectively suppresses abnormal blood vessel formation and tumor growth. This broad-spectrum kinase inhibition contributes to its effectiveness across different tumor types.

After oral administration, Lenvatinib is well absorbed and reaches steady-state plasma concentrations with continuous daily dosing. Its pharmacokinetic profile supports once-daily administration, allowing consistent therapeutic exposure.

Dosage and Administration

• Lenvanix 10 mg is taken orally once daily, with or without food.

• Dosage and treatment duration depend on the type of cancer, patient tolerance, and clinical response.

• Dose modifications may be necessary in cases of adverse reactions or organ impairment.

• Regular monitoring of blood pressure, liver function, renal function, and thyroid levels is recommended during therapy.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Key Benefits

• Broad anticancer activity through multi-kinase inhibition.

• Effective in several advanced and difficult-to-treat cancers.

• Oral once-daily dosing for patient convenience.

• Helps delay disease progression and improve clinical outcomes.

Precautions and Warnings

• Hypertension is a common and significant adverse effect; blood pressure should be well controlled before and during treatment.

• Use with caution in patients with cardiovascular disease, hepatic impairment, or renal dysfunction.

• Risk of proteinuria, bleeding events, and gastrointestinal perforation requires careful monitoring.

• Not recommended during pregnancy or breastfeeding due to potential fetal harm.

Adverse Effects

Common adverse effects include hypertension, fatigue, diarrhea, decreased appetite, weight loss, nausea, stomatitis, proteinuria, and hand-foot skin reactions. Most side effects can be managed with dose adjustment and supportive care under medical supervision.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Lenvanix 10 mg is a potent targeted therapy offering a valuable treatment option for patients with advanced cancers, combining broad kinase inhibition with the convenience of oral administration.